РусскийEnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Yemchenko J. A., Ischeykin K. E.

    EFFICIENCY OF INCLUSION METFORMIN HYDROCHLORIDE TO COMBINED THERAPY OF DISEASE PSORIATIC AND METABOLIC SYNDROME


    About the author: Yemchenko J. A., Ischeykin K. E.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation The modern doctrine of psoriasis weighty pathogenetic role of chronic inflammation that leads to metabolic and vascular disorders. According to clinical studies, psoriasis itself as a whole may be a risk factor for atherosclerosis, which is consistent with the known concepts of chronic systemic inflammation involved in the development of diseases. Clinical and experimental studies have shown that a key role in the development of atherosclerosis and psoriasis mostly play the same cytokines (IL-1, -6, TNF α, etc.). A systemic inflammatory response, which is a common pathogenetic link at such pathological conditions alters psoriasis, which leads to severe disease which responds poorly to standard treatment significantly reduces the quality of life of patients and often leads to disability. Despite the progress made in the study of the pathogenesis of psoriatic disease and metabolic syndrome, the problem of the relationship and treatment of these diseases and the prospects for their correction, today finally clarified. The purpose of our study was to increase the efficiency of the treatment of psoriatic disease with concomitant metabolic syndrome by early correction of metabolic disorders and systemic inflammation processes. We have studied the dynamics of clinical manifestations of psoriatic disease, systemic inflammation condition and carbohydrate metabolism in patients psoriatic disease and metabolic syndrome on the background inclusion in complex therapy of metformin hydrochloride traditional. In the analysis of the results of this study found that adding metformin to standard therapy in patients with psoriatic disease with metabolic syndrome improves treatment efficacy, defined by the key indicators of the clinical status of patients, systemic inflammation and insulin resistance.
    Tags psoriasis, metabolic syndrome, indicators of systemic inflammation, treatment
    Bibliography
    • Belovol A. N. Disfunkcija sosudistogo jendotelijau bol'nyh psoriazom / A. N. Belovol // Ukr. zhurn. dermatol., venerol., kosmetol.- 2010.- №1 (36).- S. 17-21.
    • Pisarzhevskij S. A. Pronicaemost' jendotelija i ateroskleroz / S. A. Pisarzhevskij // Kardiologija.- 2005.- № 12.- S. 27-42.
    • Tkachenko S. G. Kardiometabolicheskij risk u bol'nyh psorіazom / S. G. Tkachenko, V. B. Kondrashova // Dermatol. ta venerol.- 2010.- №2 (48).- S. 11-17. 
    • Charles M. Effects of weight change and metformin on fibrolysis and the von Willebrand factor in obese nondiabetic subjects. The BIGPROI Study/ M. Charles, P. Morange [et al.] // Diabetes Care. – 1998. –Vol. 21. – P. 1967-72.
    • Despres J. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes / J. Despres // Diabetes metabolism. – 2003. – R. 53-61.
    • Haffner S. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and the treatment patterns / S. Haffner // Am J Med. – 2006. - №5. – R. 3-9.
    • Henseler T. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis / T. Henseler, K. Schmitt-Rau // Int J Dermatol. –2008. - №47(10). - R. 19-23.
    • Huang N. L. Metformin inhibits TNF-alpha-induced I kappa B Kinase phosphorylation, I kappa B-alfa degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phoshorylation / N. L. Huang, S. H. Chiang, C.H. Hsveh [et al.] // Int. J. Cardiol. – 2009. – Vol.134. - N 2. – P. 169-175.
    • Lund S. S. Impact of metformin versus repaglinide on non-glycaemin cardiovascular risk markers related to inflammation and endothelial disfunction in non-oese patients with type 2 diabetes / S. S. Lund, L.T arnow, C. D. Stehouwer [et al.] // Eur. J. Endocrinol.-2008.-Vol.158. - N5. – P. 613-641.
    • Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management / K. Reich // JEADV – 2012.- Suppl. 2, №26. – R. 3-11.
    • Schӓfer T. Epidemiology of psoriasis – review and the German perspective / T. Schӓfer // Dermatology - 2006. - № 212. - S. 327-337.
    • Sommer D. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis / D.Sommer, M. Jenisch, M. Suchan // Arch. Dermatol. Res.- 2006.- Vol. 298. - № 7.- P. 321–328.
    • Sabbat R. Immunopathogenesis of psoriasis / R. Sabbat, S. Philips, C. Hoflich // Exp. Dermatol.- 2007.- Vol. 16, №9.- P. 779-798.
    • Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach / F. Späh // Br. J. Dermatol.- 2008.- Vol. 159. - Suppl 2.- R. 10-17.
    Publication of the article «World of Medicine and Biology» №4(54) 2 part 2015 year, 022-027 pages, index UDK 616.517-008.9-08